<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJCM</journal-id><journal-title-group><journal-title>International Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2158-284X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijcm.2015.67066</article-id><article-id pub-id-type="publisher-id">IJCM-58013</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  An Evans Syndrome Case Expressing Anti-Jk&lt;sup&gt;a&lt;/sup&gt; Autoantibody under Condition of Primary IgA Immunodeficiency
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>akeshi</surname><given-names>Sugimoto</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ayumi</surname><given-names>Tani</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ikuyo</surname><given-names>Hayakawa</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Makoto</surname><given-names>Hashimoto</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tomoko</surname><given-names>Yanai</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ikuko</surname><given-names>Kubokawa</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Takeshi</surname><given-names>Mori</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Takeshi</surname><given-names>Kato</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Satoshi</surname><given-names>Hirase</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nobuyuki</surname><given-names>Yamamoto</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hironobu</surname><given-names>Minami</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Akira</surname><given-names>Hayakawa</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Institute of Biomedical Research and Innovation, Kobe, Japan</addr-line></aff><aff id="aff4"><addr-line>Department of Pediatric Medicine, Kobe University Hospital, Kobe, Japan</addr-line></aff><aff id="aff1"><addr-line>Department of Hematology and Oncology, Kita-Harima Medical Center, Ono, Japan</addr-line></aff><aff id="aff3"><addr-line>Department of Blood Transfusion, Kobe University Hospital, Kobe, Japan</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>takeshi_sugimoto@kitahari-mc.jp(AS)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>07</month><year>2015</year></pub-date><volume>06</volume><issue>07</issue><fpage>496</fpage><lpage>499</lpage><history><date date-type="received"><day>24</day>	<month>June</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>11</month>	<year>July</year>	</date><date date-type="accepted"><day>16</day>	<month>July</month>	<year>2015</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Autoimmune haemolytic anaemia is a haemolytic disease resulting from an autoimmune reaction to the surface of red blood cells. A part of autoantibody is known to react with the blood type antigen. This is the case of a 14 years old female with Evans syndrome in which autoimmune haemolysis may cause from anti-Jk
  <sup>a</sup> autoantibody reaction. As this case is complicated with primary IgA immunodeficiency syndrome, anti-Jk
  <sup>a</sup> autoantibody may occur under the condition of primary immunodeficiency status, in which autoantibody production is accelerated. Considering the co-occurrence of autoimmune haemolytic anaemia and primary IgA immunodeficiency syndrome, analysis focusing on specificity for red blood cells antigens will be required in IgA immunodefi-ciency syndrome patients.
 
</p></abstract><kwd-group><kwd>Anti-Jk&lt;sup&gt;a&lt;/sup&gt; Autoantibody</kwd><kwd> Evans Syndrome</kwd><kwd> IgA Immunodeficiency</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Autoimmune haemolytic anaemia (AIHA) is a haemolytic disease resulting from an autoimmune reaction to the surface of red blood cells (RBCs). Haemolysis occurs when an autoantibody combines with an antigen on the surface of RBCs, and the antigen-antibody reaction leads to RBCs destruction. The frequency of warm type AIHA (WAIHA), which is commonly observed, is estimated to be 40% - 70% of all AIHAs. In WAIHA, the mechanism producing the autoantibody for haemolysis has not been clearly elucidated. Immunoglobulin G (IgG) reacts with a RBCs antigen commonly in a panagglutinin pattern; however, some of the autoantibody reacts with the blood type antigen, i.e., Rh blood type [<xref ref-type="bibr" rid="scirp.58013-ref1">1</xref>] . The patient presented here has Evans syndrome with primary IgA immunodeficiency syndrome (IgAD) in which haemolysis may be caused by anti-Jk<sup>a</sup> autoantibody. The objective of this report is to accumulate cases possessing autoimmune specific RBCs antigen under the primary immunodeficiency status, in order to clarify antigen specificity.</p></sec><sec id="s2"><title>2. Case Report</title><p>A 14-year-old female presented to the outpatient clinic of the Department of Paediatric Medicine, Kobe University Hospital, in July 2012 with the chief compliant of anaemia. In May 2011, she had presented with thrombocytopenia and a low titre of IgA, leading to a diagnosis of immune thrombocytopenic purpura (ITP) and IgA immunodeficiency. She had been initially treated with oral prednisolone (PSL) (1 mg/kg/day) for her ITP. Before arriving at our hospital, her PSL dose had been reduced without a recurrence of thrombocytopenia.</p><p>At the time of admission, she presented with generalized pallor, including anaemic conjunctiva. No purpura was observed, and no other abnormality was manifested. She had no history of pregnancy or receiving blood transfusions. The blood count test revealed the following: white blood cell count, 7.7 &#215; 10<sup>9</sup>/l; haemoglobin, 6.9 g/dl; hematocrit, 21.3%; reticulocytes, 9.8%; and platelet count, 349 &#215; 10<sup>9</sup>/μl, that was consistent with anaemia. Serological tests indicated some abnormality: LD, 250 IU/l; indirect bilirubin, 5.6 mg/dl; and haptoglobin, &lt;10 mg/dl. Immunological tests confirmed primary IgAD that revealed a remarkable decrease of IgA, the level of which was &lt;4 mg/dl (normal range, 110 - 410 mg/dl), with a normal range of other immunoglobulin subtypes. Complement titre (CH50) was decreased to 12.8 U/ml (normal, 30 - 45 U/ml) without C3 or C4 depression. Blood typing revealed type B and rhesus D positive (CCDee). Direct antiglobulin test (DAT) was positive, and monospecific DAT test with anti-IgG and anti-C3d anti-serum were both positive (anti-IgG, 2+; anti-C3d, 3+). Indirect antiglobulin test (IAT) was strongly positive for all panel blood cells. These results indicated that she had AIHA.</p><p>The antibody identification test using Panel Cell<sup>&#174;</sup> (Ortho-Clinical Diagnostics) with polyethylene glycol (Immucor Inc.) and IAT method revealed a Jk(a)-specific reaction. IAT using the antibody-eluted sample from the patient’s RBC by Gamma-Quin<sup>&#174;</sup> (Immucor Inc.) had a non-specific positive reaction, whereas the IAT test using the 16-times diluted sample prepared from the original eluted sample was Jk(a)-specific phenotype with no other reaction. Therefore, the patient was diagnosed with AIHA with anti-Jk<sup>a</sup> autoantibody. As her thrombocytopenia had been previously diagnosed as ITP, she was diagnosed with Evans syndrome (AIHA associated with immune thrombocytopenia). Immediately after her hospital admission in July 2012, the patient complained of dizziness, and her haemoglobin level decreased to 5.3 g/dl (<xref ref-type="fig" rid="fig1">Figure 1</xref>). She received two units of Jk(a) antigen- negative red blood cells with washing. Oral PSL therapy (1 mg/kg/day) was initiated. Her haemoglobin level transiently increased after red blood cells transfusion, whereas thrombocytopenia exacerbated after initiating PSL therapy. Haptoglobin increased to a normal level after PSL administration. Thrombocytopenia and haemolytic anaemia gradually improved by the end of August 2012. PSL treatment was reduced and stopped two months post-admission. However, the patient presented in December 2012 with thrombocytopenia without complicating anaemia; she received oral PSL therapy (1 mg/kg/day), leading to the improvement of thrombocytopenia. PSL treatment could be reduced by the normalization of platelet counts (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec id="s3"><title>3. Discussion</title><p>This was an Evans syndrome case in which autoimmune haemolysis was caused by a Jk(a) antigen-antibody reaction. Since this patient had neither received a blood transfusion nor had a history of pregnancy before, we speculate that haemolysis may be caused by anti-Jk<sup>a</sup> autoantibody. Among the autoantibodies able to cross-react with RBCs antigens, Rh type is the most popular [<xref ref-type="bibr" rid="scirp.58013-ref2">2</xref>] . Kidd group autoantibody, without being induced by drugs, is rarely recognized. Nine reports of haemolysis occurring due to anti-Jk<sup>a</sup> autoantibody have been previously reported [<xref ref-type="bibr" rid="scirp.58013-ref3">3</xref>] -[<xref ref-type="bibr" rid="scirp.58013-ref11">11</xref>] , of which three cases manifested as Evans syndrome [<xref ref-type="bibr" rid="scirp.58013-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.58013-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.58013-ref10">10</xref>] (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>Primary hypo-gammagulobulinemia, including IgAD, has the tendency to complicate autoimmune diseases</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Clinical course. Abbreviations: Hb, haemoglobin; LD, lactate dehydrogenase; Plt, platelet count; PSL, prednisolone; RBC, red blood cells; T-Bil, total bilirubin</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/10-2101148x6.png"/></fig><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Summary of cases possessing Kidd blood group autoantibody</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Age/ gender</th><th align="center" valign="middle" >Antigen</th><th align="center" valign="middle" >Hb (g/dl)</th><th align="center" valign="middle" >ITP (Evans)</th><th align="center" valign="middle" >Complicated disease at the diagnosis of AIHA</th><th align="center" valign="middle" >Medication</th><th align="center" valign="middle" >Author (year)</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >45/M</td><td align="center" valign="middle" >Jk<sup>a</sup></td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >＋</td><td align="center" valign="middle" >Neutropenia</td><td align="center" valign="middle" >PSL</td><td align="center" valign="middle" >Ciaffoni S [<xref ref-type="bibr" rid="scirp.58013-ref3">3</xref>] (1987)</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0/F</td><td align="center" valign="middle" >Jk<sup>a</sup></td><td align="center" valign="middle" >5.2</td><td align="center" valign="middle" >－</td><td align="center" valign="middle" >Bacterial meningitis</td><td align="center" valign="middle" >RBC. PSL</td><td align="center" valign="middle" >Sander RP [<xref ref-type="bibr" rid="scirp.58013-ref4">4</xref>] (1987)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >34/M</td><td align="center" valign="middle" >Jk<sup>a</sup></td><td align="center" valign="middle" >4.9</td><td align="center" valign="middle" >＋</td><td align="center" valign="middle" >No complication</td><td align="center" valign="middle" >RBC, IVIG, Splenectomy, PSL, AZA, VCR</td><td align="center" valign="middle" >Ganly PS [<xref ref-type="bibr" rid="scirp.58013-ref5">5</xref>] (1988)</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >49/M</td><td align="center" valign="middle" >Jk<sup>a</sup></td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >－</td><td align="center" valign="middle" >Lung cancer</td><td align="center" valign="middle" >－</td><td align="center" valign="middle" >Wernli RY [<xref ref-type="bibr" rid="scirp.58013-ref6">6</xref>] (1990)</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >38/F</td><td align="center" valign="middle" >Jk<sup>a</sup> + Jk<sup>b</sup></td><td align="center" valign="middle" >7.5</td><td align="center" valign="middle" >－</td><td align="center" valign="middle" >Systemic lupus erythematosus</td><td align="center" valign="middle" >RBC, PSL</td><td align="center" valign="middle" >Grishaber JE [<xref ref-type="bibr" rid="scirp.58013-ref7">7</xref>] (1992)</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >60/M</td><td align="center" valign="middle" >Jk<sup>a</sup></td><td align="center" valign="middle" >6.3</td><td align="center" valign="middle" >－</td><td align="center" valign="middle" >Ulcerative colitis</td><td align="center" valign="middle" >RBC</td><td align="center" valign="middle" >Guastafierro S [<xref ref-type="bibr" rid="scirp.58013-ref8">8</xref>] (2004)</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >19/F</td><td align="center" valign="middle" >Jk<sup>a</sup></td><td align="center" valign="middle" >1.9</td><td align="center" valign="middle" >－</td><td align="center" valign="middle" >Systemic lupus erythematosus</td><td align="center" valign="middle" >PSL, IVIG</td><td align="center" valign="middle" >Wondergem MJ [<xref ref-type="bibr" rid="scirp.58013-ref9">9</xref>] (2006)</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >54/M</td><td align="center" valign="middle" >Jk<sup>a</sup></td><td align="center" valign="middle" >6.5</td><td align="center" valign="middle" >＋</td><td align="center" valign="middle" >Common variable immunodeficiency</td><td align="center" valign="middle" >PSL, IVIG</td><td align="center" valign="middle" >Garcia-Munoz R [<xref ref-type="bibr" rid="scirp.58013-ref10">10</xref>] (2008)</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >5/F</td><td align="center" valign="middle" >Jk<sup>a</sup></td><td align="center" valign="middle" >4.1</td><td align="center" valign="middle" >－</td><td align="center" valign="middle" >Parvovirus B19 infection</td><td align="center" valign="middle" >Intravenous mPSL</td><td align="center" valign="middle" >Giovannetti G [<xref ref-type="bibr" rid="scirp.58013-ref11">11</xref>] (2013)</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >14/F</td><td align="center" valign="middle" >Jk<sup>a</sup></td><td align="center" valign="middle" >6.4</td><td align="center" valign="middle" >＋</td><td align="center" valign="middle" >Selective IgA immunodeficiency</td><td align="center" valign="middle" >RBC, PSL</td><td align="center" valign="middle" >(Our case)</td></tr></tbody></table></table-wrap><p>Abbreviations: AZA, Azathioprine; IVIG, Intravenous immunoglobulin; VCR, Vincristine; PSL, Prednisolone; mPSL, Methylprednisolone; RBC, Red blood cells; Jk<sup>a</sup>, Jk<sup>a</sup> autoantibody; Jk<sup>b</sup>, Jk<sup>b</sup> autoantibody; M, Male; F, Female.</p><p>[<xref ref-type="bibr" rid="scirp.58013-ref12">12</xref>] -[<xref ref-type="bibr" rid="scirp.58013-ref14">14</xref>] . Autoimmune haematological diseases, including ITP or AIHA, are most frequently observed in primary immunodeficiency diseases [<xref ref-type="bibr" rid="scirp.58013-ref15">15</xref>] . The diagnosis of IgAD occurs when IgA is &lt;7 mg/dl with a concomitant normal level of IgG and IgM [<xref ref-type="bibr" rid="scirp.58013-ref15">15</xref>] . With regard to IgAD, the frequency of complicating AIHA or ITP was reported as 2% - 3% or 0.5%, respectively [<xref ref-type="bibr" rid="scirp.58013-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.58013-ref16">16</xref>] . In 10 AIHA cases caused by autoimmune Jk(a) antibody including ours, two cases were complicated primary immunodeficiency syndrome, i.e. one case of common variable immunodeficiency (CVID) [<xref ref-type="bibr" rid="scirp.58013-ref10">10</xref>] and our case of IgAD. In terms of autoimmune Jk(a) antibody, the frequency of carrying the background of immunodeficiency seems to be high. The reason for autoimmune disease, including AIHA from IgAD, is not conclusive; however, one hypothesis is that a dysfunction of SHP-1 tyrosine phosphate is related to the inhibitory immunoreceptor tyrosine-based activation motif in IgAD, resulting in hyper-activation of immune cells [<xref ref-type="bibr" rid="scirp.58013-ref16">16</xref>] . The evidence regarding the causative antigen in AIHA in primary immunodeficiency disease, including IgAD or CVID, is lacking. Considering the co-occurrence of AIHA and primary immune-deficient diseases, analysis focusing on specificity for RBC antigens will be required to perform adequate transfusion and understand autoimmune conditions.</p></sec><sec id="s4"><title>4. Conclusion</title><p>Autoimmune haematological diseases, including ITP or AIHA, are most frequently observed in primary immunodeficiency diseases. Antigen analysis for autoimmune haemolysis will be considered under condition of primary IgAD.</p></sec><sec id="s5"><title>Disclosure Statement</title><p>The authors declare no conflict of interest.</p></sec><sec id="s6"><title>Cite this paper</title><p>TakeshiSugimoto,AyumiTani,IkuyoHayakawa,MakotoHashimoto,TomokoYanai,IkukoKubokawa,TakeshiMori,TakeshiKato, SatoshiHirase,NobuyukiYamamoto,HironobuMinami,AkiraHayakawa, (2015) An Evans Syndrome Case Expressing Anti-Jk<sup>a</sup> Autoantibody under Condition of Primary IgA Immunodeficiency. International Journal of Clinical Medicine,06,496-499. doi: 10.4236/ijcm.2015.67066</p></sec><sec id="s7"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.58013-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Klein, H.G. and Anstee, D.J. (2006) Mollison’s Blood Transfusion in Clinical Medicine. 11th Edition, Blackwell Publishing, Hoboken, 268.</mixed-citation></ref><ref id="scirp.58013-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Reid, M.E., Lomas-Francis, C. and Olsson, M.L. (2012) The Blood Group Antigen Facts Book. 3rd Edition, Academic Press, Waltham, 378.</mixed-citation></ref><ref id="scirp.58013-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ciaffoni, S., Ferro, I., Potenza, R. and Campo, G. (1987) Evans Syndrome: A Case of Autoimmune Thrombocytopenia and Autoimmune Hemolytic Anemia Caused by Anti-Jka. Haematologica, 72, 245-247.</mixed-citation></ref><ref id="scirp.58013-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Sander, R.P., Hardy, N.M. and Van Meter, S.A. (1987) Anti-Jka Autoimmune Hemolytic Anemia in an Infant. Transfusion, 27, 58-60. http://dx.doi.org/10.1046/j.1537-2995.1987.27187121475.x</mixed-citation></ref><ref id="scirp.58013-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ganly, P.S., Laffan, M.A., Owen, I. and Hows, J.M. (1988) Auto-Anti-Jka in Evans’ Syndrome with Negative Direct Antiglobulin Test. British Journal of Haematology, 69, 537-539. http://dx.doi.org/10.1111/j.1365-2141.1988.tb02411.x</mixed-citation></ref><ref id="scirp.58013-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wernli, R.Y., Strauss, R.G. and Cordle, D.G. (1990) A Patient with Transient Autoanti-Jka. Acta Haematologica, 84, 190-192. http://dx.doi.org/10.1159/000205061</mixed-citation></ref><ref id="scirp.58013-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Grishaber, J.E., Cordle, D.G. and Strauss, R.G. (1992) Development of Alloanti-Jka in a Patient with Hemolytic Anemia Due to Autoanti-Jkb. American Journal of Clinical Pathology, 98, 542-544.</mixed-citation></ref><ref id="scirp.58013-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Guastafierro, S., Sessa, F., Cuomo, C. and Tirelli, A. (2004) Delayed Hemolytic Transfusion Reaction Due to Anti-S Antibody in Patient with Anti-Jk(a) Autoantibody and Multiple Alloantibodies. Annals of Hematology, 83, 307-308. http://dx.doi.org/10.1007/s00277-003-0794-y</mixed-citation></ref><ref id="scirp.58013-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wondergem, M.J., Overbeeke, M., Som, N., Chamuleau, M.E., Jonkhoff, A.R. and Zweegman, S. (2006) Mixed Autoimmune Haemolysis in a SLE Patient Due to Aspecific and Anti-Jka Autoantibodies; Case Report and Review of the Literature. Haematologica, 91, ECR12.</mixed-citation></ref><ref id="scirp.58013-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Garcia-Munoz, R., Anton, J., Rodriguez-Otero, P., Moreno, C., Sanchez-Ibarrola, A., Seijo, L.M. and Paramo, J.A. (2008) Common Variable Immunodeficiency and Evans Syndrome Complicated by Autoimmune Hemolysis Due to Anti-Jka Auto-Antibodies. Leukemia Lymphoma, 49, 1220-1222. http://dx.doi.org/10.1080/10428190801993488</mixed-citation></ref><ref id="scirp.58013-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Giovannetti, G., Pauselli, S., Barrella, G., Neri, A., Antonetti, L., Gentile, G., Iacobini, M., Girelli, G. and Coluzzi, S. (2013) Severe Warm Autoimmune Haemolytic Anaemia Due to Anti-Jk(a) Autoantibody Associated with Parvovirus B19 Infection in a Child. Blood Transfusion, 11, 634-635.</mixed-citation></ref><ref id="scirp.58013-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Arason, G.J., Jorgensen, G.H. and Ludviksson, B.R. (2010) Primary Immunodeficiency and Autoimmunity: Lessons from Human Diseases. Scandinavian Journal of Immunology, 71, 317-328. http://dx.doi.org/10.1111/j.1365-3083.2010.02386.x</mixed-citation></ref><ref id="scirp.58013-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Aytekin, C., Tuygun, N., Gokce, S., Dogu, F. and Ikinciogullari, A. (2012) Selective IgA Deficiency: Clinical and Laboratory Features of 118 Children in Turkey. Journal of Clinical Immunology, 32, 961-966. http://dx.doi.org/10.1007/s10875-012-9702-3</mixed-citation></ref><ref id="scirp.58013-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Agarwal, S. and Cunningham-Rundles, C. (2009) Autoimmunity in Common Variable Immunodeficiency. Current Allergy and Asthma Reports, 9, 347-352. http://dx.doi.org/10.1007/s11882-009-0051-0</mixed-citation></ref><ref id="scirp.58013-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Cunningham-Rundles, C. (2002) Hematologic Complications of Primary Immune Deficiencies. Blood Reviews, 16, 61-64. http://dx.doi.org/10.1054/blre.2001.0185</mixed-citation></ref><ref id="scirp.58013-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Jacob, C.M., Pastorino, A.C., Fahl, K., Carneiro-Sampaio, M. and Monteiro, R.C. (2008) Autoimmunity in IgA Deficiency: Revisiting the Role of IgA as a Silent Housekeeper. Journal of Clinical Immunology, 28, 56-61.http://dx.doi.org/10.1007/s10875-007-9163-2</mixed-citation></ref></ref-list></back></article>